These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 33153234)

  • 1. The Pyrazolo[3,4-
    Neuber C; Tröster A; Löser R; Belter B; Schwalbe H; Pietzsch J
    Molecules; 2020 Nov; 25(21):. PubMed ID: 33153234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of Receptor Tyrosine Kinase EphB4 Triggers Tumor Growth and Hypoxia in A375 Melanoma Xenografts: Insights from Multitracer Small Animal Imaging Experiments.
    Neuber C; Belter B; Meister S; Hofheinz F; Bergmann R; Pietzsch HJ; Pietzsch J
    Molecules; 2018 Feb; 23(2):. PubMed ID: 29462967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis.
    Martiny-Baron G; Holzer P; Billy E; Schnell C; Brueggen J; Ferretti M; Schmiedeberg N; Wood JM; Furet P; Imbach P
    Angiogenesis; 2010 Sep; 13(3):259-67. PubMed ID: 20803239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family.
    Tröster A; Heinzlmeir S; Berger BT; Gande SL; Saxena K; Sreeramulu S; Linhard V; Nasiri AH; Bolte M; Müller S; Kuster B; Médard G; Kudlinzki D; Schwalbe H
    ChemMedChem; 2018 Aug; 13(16):1629-1633. PubMed ID: 29928781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EPHB4 tyrosine-kinase receptor expression and biological significance in soft tissue sarcoma.
    Becerikli M; Merwart B; Lam MC; Suppelna P; Rittig A; Mirmohammedsadegh A; Stricker I; Theiss C; Singer BB; Jacobsen F; Steinstraesser L
    Int J Cancer; 2015 Apr; 136(8):1781-91. PubMed ID: 25274141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pyrazolo-pyrimidine-derived c-Src inhibitor reduces angiogenesis and survival of squamous carcinoma cells by suppressing vascular endothelial growth factor production and signaling.
    Donnini S; Monti M; Castagnini C; Solito R; Botta M; Schenone S; Giachetti A; Ziche M
    Int J Cancer; 2007 Mar; 120(5):995-1004. PubMed ID: 17131343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EphB4/ TNFR2/ERK/MAPK signaling pathway comprises a signaling axis to mediate the positive effect of TNF-α on osteogenic differentiation.
    Zhang Y; Yang C; Ge S; Wang L; Zhang J; Yang P
    BMC Mol Cell Biol; 2020 Apr; 21(1):29. PubMed ID: 32299362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EphB4 forward signalling mediates angiogenesis caused by CCM3/PDCD10-ablation.
    You C; Zhao K; Dammann P; Keyvani K; Kreitschmann-Andermahr I; Sure U; Zhu Y
    J Cell Mol Med; 2017 Sep; 21(9):1848-1858. PubMed ID: 28371279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The small molecule tyrosine kinase inhibitor NVP-BHG712 antagonizes ABCC10-mediated paclitaxel resistance: a preclinical and pharmacokinetic study.
    Kathawala RJ; Wei L; Anreddy N; Chen K; Patel A; Alqahtani S; Zhang YK; Wang YJ; Sodani K; Kaddoumi A; Ashby CR; Chen ZS
    Oncotarget; 2015 Jan; 6(1):510-21. PubMed ID: 25402202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance to bevacizumab in ovarian cancer SKOV3 xenograft due to EphB4 overexpression.
    Li L; Nan F; Guo Q; Guan D; Zhou C
    J Cancer Res Ther; 2019; 15(6):1282-1287. PubMed ID: 31898661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Homoharringtonine suppresses LoVo cell growth by inhibiting EphB4 and the PI3K/AKT and MAPK/EKR1/2 signaling pathways.
    Shi X; Zhu M; Gong Z; Yang T; Yu R; Wang J; Zhang Y
    Food Chem Toxicol; 2020 Feb; 136():110960. PubMed ID: 31726078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PDGFRβ reverses EphB4 signaling in alveolar rhabdomyosarcoma.
    Aslam MI; Abraham J; Mansoor A; Druker BJ; Tyner JW; Keller C
    Proc Natl Acad Sci U S A; 2014 Apr; 111(17):6383-8. PubMed ID: 24733895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EphB4 promotes site-specific metastatic tumor cell dissemination by interacting with endothelial cell-expressed ephrinB2.
    Héroult M; Schaffner F; Pfaff D; Prahst C; Kirmse R; Kutschera S; Riedel M; Ludwig T; Vajkoczy P; Graeser R; Augustin HG
    Mol Cancer Res; 2010 Oct; 8(10):1297-309. PubMed ID: 21047731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ephrin-B2-EphB4 communication mediates tumor-endothelial cell interactions during hematogenous spread to spinal bone in a melanoma metastasis model.
    Broggini T; Piffko A; Hoffmann CJ; Ghori A; Harms C; Adams RH; Vajkoczy P; Czabanka M
    Oncogene; 2020 Nov; 39(47):7063-7075. PubMed ID: 32989254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EphB4 overexpression in B16 melanoma cells affects arterial-venous patterning in tumor angiogenesis.
    Huang X; Yamada Y; Kidoya H; Naito H; Nagahama Y; Kong L; Katoh SY; Li WL; Ueno M; Takakura N
    Cancer Res; 2007 Oct; 67(20):9800-8. PubMed ID: 17942910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Forward and Reverse EphB4/EFNB2 Signaling by a Peptide with Dual Functions.
    Xiong C; Wen Y; Zhao J; Yin D; Xu L; Chelariu-Raicu A; Yao C; Leng X; Liu J; Chaudhari RR; Zhang S; Sood AK; Li C
    Sci Rep; 2020 Jan; 10(1):520. PubMed ID: 31949258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting receptor tyrosine kinase EphB4 in cancer therapy.
    Chen Y; Zhang H; Zhang Y
    Semin Cancer Biol; 2019 Jun; 56():37-46. PubMed ID: 28993206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EphB4 signaling is capable of mediating ephrinB2-induced inhibition of cell migration.
    Sturz A; Bader B; Thierauch KH; Glienke J
    Biochem Biophys Res Commun; 2004 Jan; 313(1):80-8. PubMed ID: 14672701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Eph receptor signaling as a regulator of autophagy and a therapeutic target in colorectal carcinoma.
    DiPrima M; Wang D; Tröster A; Maric D; Terrades-Garcia N; Ha T; Kwak H; Sanchez-Martin D; Kudlinzki D; Schwalbe H; Tosato G
    Mol Oncol; 2019 Nov; 13(11):2441-2459. PubMed ID: 31545551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BCR-ABL-independent and RAS / MAPK pathway-dependent form of imatinib resistance in Ph-positive acute lymphoblastic leukemia cell line with activation of EphB4.
    Suzuki M; Abe A; Imagama S; Nomura Y; Tanizaki R; Minami Y; Hayakawa F; Ito Y; Katsumi A; Yamamoto K; Emi N; Kiyoi H; Naoe T
    Eur J Haematol; 2010 Mar; 84(3):229-38. PubMed ID: 20002159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.